Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder-Reference-Cited by-同舟云学术

Economic burden of treatment-resistant depression in privately insured US patients with co-occurring anxiety disorder and/or substance use disorder

Published:2020-11-18 Issue:1 Volume:37 Page:123-133
ISSN:0300-7995
Container-title:Current Medical Research and Opinion
language:en
Short-container-title:Current Medical Research and Opinion

Author:

Zhdanava Maryia¹,Kuvadia Harsh²,Joshi Kruti³,Daly Ella³,Pilon Dominic¹,Rossi Carmine¹,Morrison Laura¹,Lefebvre Patrick¹,Nelson Craig⁴

Affiliation:

1. Analysis Group Inc., Montréal, Canada

2. Integrated Resources Inc., Edison, NJ, USA

3. Janssen Scientific Affairs LLC, Titusville, NJ, USA

4. Department of Psychiatry, University of California, San Francisco, CA, USA

Funder

Janssen Scientific Affairs LLC.

Publisher

Informa UK Limited

Subject

General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/03007995.2020.1844645

Reference40 articles.

1. Substance Abuse and Mental Health Services Administration. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54) [Internet]. Rockville (MD): Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration

2. 2019 [cited 2019 Nov 13]. Available from: https://www.samhsa.gov/data/

3. National Institute of Mental Health (NIMH). Major depression factsheet [Internet]. 2019 [cited 2019 Aug 1]. Available from: https://www.nimh.nih.gov/health/statistics/major-depression.shtml

4. Joshi K, Zhdanava M, Pilon D, et al. Health care use and associated cost among patients with treatment-resistant depression across payers: a comprehensive analysis. Poster presented at the Academy of Managed Care Pharmacy (AMCP) Annual Meeting; 2019 Mar 25–28; San Diego, CA.

5. Characterization of Treatment Resistant Depression Episodes in a Cohort of Patients from a US Commercial Claims Database

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans;Journal of Medical Economics;2023-03-22

2. Polysomnographic identification of anxiety and depression using deep learning;Journal of Psychiatric Research;2022-06

3. Patient profiles, initial hospital encounter characteristics, and hospital re-encounters of patients with a hospital emergency department visit or inpatient admission for major depressive disorder;Journal of Medical Economics;2022-02-03

4. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States;Advances in Therapy;2021-12-17

5. Anhedonia difference between major depressive disorder and bipolar disorder II;BMC Psychiatry;2021-10-27